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Abstract
The management of the ongoing lymphogranuloma venereum epi-
demic in industrialized Western countries caused by Chlamydia
trachomatis variant L2b still needs improvements in diagnosis,
therapy and prevention. We therefore developed the ﬁrst rapid
C. trachomatis variant L2b-speciﬁc polymerase chain reaction to
circumvent laborious ompA gene sequencing.
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Lymphogranuloma venereum (LGV) is caused by Chlamydia
trachomatis serovars L1–L3. LGV is more invasive than infec-
tions caused by the oculo-genital C. trachomatis serovars
D–K. It classically manifests itself as an inguinal syndrome,
with genital ulceration, inguinal lymphadenopathy (buboes),
and subsequent suppuration. But it can also cause a severe
anorectal syndrome, with proctocolitis and hyperplasia of
intestinal and perirectal lymphatic tissue [1]. LGV is endemic
in Africa, southeast Asia and the Caribbean. It is a sporadic
disease in Europe and North America.
In 2003, an LGV outbreak was reported in the Nether-
lands and other Western European countries among men
who have sex with men (MSM). The European Surveillance
of Sexually Transmitted Infections (http://www.essti.org) and
the Centers for Disease Control and Prevention (http://
www.cdc.gov) instigated warning and response systems to
increase the awareness and the management of the LGV out-
break, but the outbreak is still ongoing [1–8].
In 2005, we identiﬁed a unique single-nucleotide mutation
in the ompA gene of the LGV L2 serovar circulating among
MSM. This serovariant was designated L2b [2]. Subsequently
we developed a speciﬁc LGV real-time polymerase chain
reaction (PCR) exploiting a unique deletion (36 bp) in all
LGV serovars within the polymorphic membrane protein H
(pmpH) gene [3].
In our laboratories in Amsterdam and Basel we get fre-
quent epidemiology-based requests to identify the aetiologi-
cal LGV serovar as the L2b variant. To identify the L2b
mutation in the variable segment 2 of the ompA gene, we
have to amplify and sequence this fragment. To avoid the
high costs of sequencing and the need for sophisticated
equipment, we developed an L2b-speciﬁc primer/probe set
using fast and reliable real-time PCR techniques for identiﬁ-
cation of the L2b variant.
The Study
We sequenced the pmpH gene (2952 bp) of two serovariant
L2b-containing clinical specimens (accession numbers
EF534758 and EF612788), which were 100% identical, and
compared them with a reference sequence from serovar L2.
To our surprise we identiﬁed several unique differences
(Figs 1 and 2). First, L2b has a single-nucleotide polymorphism
at the second base where the previously developed LGV-spe-
ciﬁc probe binds, just besides the 36-bp deletion (Fig. 1).
Based on this ﬁnding we adjusted our previously published [3]
probe: instead of a C base, we incorporated a degenerated
base (C/T) to be able to detect all LGV serovars and variants
L1, L2, L2a, L2b and L3 adequately. Additionally, we identiﬁed
a 9-bp insertion unique for L2b resulting in a repeat sequence
(TCT AGT AGT)2 (Fig. 2). These two sequence heterogeneities
were then conﬁrmed in another ten L2b-positive samples by
sequencing. We veriﬁed whether the insertion is unique
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FIG. 1. LGV-speciﬁc probe: alignment of partial pmpH gene of C. trachomatis serovars. L2b sequence used as reference (accession numbers
EF534758 and EF612788). Nucleotide numbers are relative to the start codon. The mutation in L2b is marked by the red rectangle. The ﬁrst
four lines represent the LGV serovars. Probe represents the LGV-speciﬁc MGB-probe, A–K represent the ocular and urogenital C. trachomatis
serovars. SW-E is the Swedish variant of serovar E. The dashed lines within the LGV serovars represent the LGV-speciﬁc deletion sequence.
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FIG. 2. L2b-speciﬁc PCR: alignment of partial pmpH gene of C. trachomatis serovars. L2b sequence used as reference (accession numbers
EF534758 and EF612788). Nucleotide numbers are relative to the start codon. The unique insertion of the L2b serovariant is located at relative
position 1885–1893. The newly developed probe covers the repeat (TCT AGT AGT)2. Forward, Reverse and Probe represent the primers and
MGB-probe of the L2b-speciﬁc PCR, L1–L3 and A–K represent the C. trachomatis LGV and oculogenital serovars, respectively. The reverse pri-
mer depicted here is the reverse complimentary sequence of the actual reverse primer.
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among all C. trachomatis serovars. Using BioEdit Sequence
Alignment Editor we aligned the sequences of pmpH genes of
19 serovars/serovariants (NCBI accession number in brack-
ets): A (AY184155), B (AY184156), Ba (AY184157), C
(AY184158), D (AY184159), Da (AY967759), E (AY184160),
Swedish variant E (SW-E; FN652779), F (AY184161), G
(AY184162), H (AY184163), I (AY184164), Ia (AY967760), J
(AY184165), K (AY184166), L1 (AY184167), L2 (AY184168)
and L3 (AY184169). The analysis conﬁrmed the unique nature
of the insert of L2b within the pmpH gene (Fig. 2). Our
sequence ﬁndings have also been conﬁrmed by the recent
publication of the entire L2b genome [9] (accession no.
NC_010280). The following primers and probe were selected
based on this unique insertion: L2b-F 5¢ TCG CTG ACG ATT
CCT TTT GTT 3¢, L2b-R 5¢ CGC TTC ATT GTA ACC CCG
TTA 3¢, and L2b MGB-probe 5¢ VIC-CTT CTA GTA GTT
CTA GTA GTG CT-MGB 3¢. Standard TaqMan conditions
with 45 cycles of 15 s at 95C and 1 min at 60C were used
for PCR ampliﬁcation.
We compared our old LGV probe with the adjusted LGV
probe within the LGV-speciﬁc deletion region. We tested
C. trachomatis L1, L2, L2a, L2b and L3 reference strains.
Using titrated serial dilutions we found a slightly increased
analytical sensitivity (factor 2–20) of our new LGV assay for
the detection of L2b. Although we found this increased ana-
lytical sensitivity, every L2b case previously tested was
detected by both the old and new LGV assay. No differences
were observed for the other serovars tested, showing a
well-deﬁned LGV-speciﬁc PCR.
To determine speciﬁcity of the newly developed L2b-spe-
ciﬁc insertion probe, we ﬁrstly analysed different Chlamydia
strains: C. trachomatis (serovars/serovariants, A, B, Ba, C, D,
Da, D-, E, F, G, Ga, H, I, Ia, J, K, L1, L2, L2a, L3), C. muridarum
(MoPn), C. pneumoniae, C. pecorum and C. psittaci. Secondly,
we tested 31 microorganisms found in the perianal and uro-
genital regions and the oropharynx: Bacteroides spp. (ao. fragi-
lis), Clostridium spp. (ao. novyi), Faecalibacterium prausnitzii,
Atopobium parvulum, Enterococcus faecalis, Propionibacterium
acnes, Bordetella pertussis, Neisseria gonorrhoeae, Mycoplasma
pneumoniae, Legionella pneumophila, Bartonella henselae, Myco-
bacterium tuberculosis, Streptococcus pyogenes, Staphylococcus
aureus and Saccharomyces cerevisiae. Thirdly, we isolated DNA
from C. trachomatis- and LGV-negative rectal swaps obtained
from ten healthy men. Isolated DNA of these samples
included (unknown) microorganisms commonly found in the
rectum. Finally, we included a series of 60 ompA-based L2b-
positive clinical isolates from Switzerland, the Netherlands
and Italy (see Table 1 for an overview of the results).
The results showed that only the samples that had been
previously diagnosed as L2b by ompA sequencing tested posi-
tive with the new insertion assay. There was no cross-reac-
tivity with either the Chlamydia serovars/serovariants,
including L2 and L2a, Chlamydia species or the other tested
bacteria and clinical samples. In addition, we found equal sen-
sitivity of the new L2b-speciﬁc and our adjusted LGV-speciﬁc
PCR performing serial dilution tests. As expected, the gen-
eral C. trachomatis plasmid PCR, targeting around ten cryptic
plasmids, had a 10–50 times higher analytical sensitivity in
serial dilutions.
Conclusions
The prevalence of LGV is still increasing in many European
countries since the ﬁrst reports of the LGV epidemic in
2003 [10]. Almost all strains causing this LGV epidemic are
L2b [11–13]. Mapping the spread and prevalence of LGV
serovariant L2b speciﬁcally may provide answers to impor-
tant epidemiological questions that are needed for disease
control and prevention. Therefore, a fast and highly accurate
detection assay is a prerequisite. Our new LGV L2b test ful-
ﬁlls all these requirements and omits the laborious ompA
sequencing step.
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TABLE 1. Overview of the LGV L2b test results
L2b RT-PCR test results
Positive with
L2b RT-PCR
Negative with
L2b RT-PCR
C. trachomatis serovars A–K – All
C. trachomatis serovars L1, L2, L2a, L3 – All
C. muridarum (MoPn), C. pneumoniae,
C. pecorum, C. psittaci
– All
31 commonly found microorganisms* – All
Ten rectal swaps of healthy men – All
60 L2b-positive samples All –
*These 31 microorganisms are commonly found in the urogenital and anorectal
tract, or in the oropharynx.
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